- Home
- MRBK vs NERV Comparison
MRBK vs NERV Comparison
Compare MRBK & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MRBK | NERV |
|---|---|---|
| Founded | 2004 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 198.4M | 189.1M |
| IPO Year | 2017 | 2014 |
Fundamental Metrics
Financial Performance| Metric | MRBK | NERV |
|---|---|---|
| Price | $18.30 | $4.37 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 3 | 1 |
| Target Price | ★ $18.00 | $4.00 |
| AVG Volume (30 Days) | 68.8K | ★ 74.6K |
| Earning Date | 01-23-2026 | 02-24-2026 |
| Dividend Yield | ★ 2.73% | N/A |
| EPS Growth | ★ 75.95 | N/A |
| EPS | ★ 1.77 | N/A |
| Revenue | ★ $109,758,000.00 | N/A |
| Revenue This Year | $26.48 | N/A |
| Revenue Next Year | $7.79 | N/A |
| P/E Ratio | $10.36 | ★ N/A |
| Revenue Growth | ★ 18.84 | N/A |
| 52 Week Low | $11.16 | $1.15 |
| 52 Week High | $19.24 | $12.46 |
Technical Indicators
Market Signals| Indicator | MRBK | NERV |
|---|---|---|
| Relative Strength Index (RSI) | 57.50 | 53.98 |
| Support Level | $18.10 | $3.75 |
| Resistance Level | $19.24 | $4.65 |
| Average True Range (ATR) | 0.47 | 0.35 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 52.31 | 55.88 |
Price Performance
Historical ComparisonAbout MRBK Meridian Corporation
Meridian Corp is a bank holding company. Through its banking subsidiary, it operates as a full-service, state-chartered commercial bank providing personal, business lending, and deposit services. It operates in three reportable segments including Bank, Wealth, and Mortgage. The company generates maximum revenue from the Bank segment which consists of commercial and retail banking. It generates interest income from its lending (including leasing) and investing activities and is dependent on the gathering of lower-cost deposits from its branch network or borrowed funds from other sources for funding its loans.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.